Compare MANU & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MANU | IRON |
|---|---|---|
| Founded | 1878 | 2017 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.6B |
| IPO Year | 2012 | 2020 |
| Metric | MANU | IRON |
|---|---|---|
| Price | $21.99 | $78.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | $23.19 | ★ $126.77 |
| AVG Volume (30 Days) | 238.4K | ★ 1.5M |
| Earning Date | 11-19-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.71 | N/A |
| Revenue Next Year | $6.21 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.85 | $40.00 |
| 52 Week High | $24.45 | $99.50 |
| Indicator | MANU | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 51.79 | 51.16 |
| Support Level | $20.82 | $74.31 |
| Resistance Level | $23.67 | $83.56 |
| Average True Range (ATR) | 0.71 | 3.88 |
| MACD | 0.04 | -0.37 |
| Stochastic Oscillator | 44.71 | 10.99 |
Manchester United PLC operates as a professional football club with related activities, generating revenue prominently through commercial, broadcasting, and matchday segments. The commercial segment monetizes the various brands via sponsorships, retail, merchandising, apparel, and product licensing. Broadcasting revenue comes from television rights linked to football leagues and competitions, alongside content delivered through its dedicated TV channel all over the globe. Matchday income includes ticket sales, hospitality, merchandise, and services at its stadium. Manchester United is based in England. The company's operations and fan base extend to many countries, supporting a diversified revenue model based on brand engagement and football-related content.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.